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1999). However, the only example of a
ribozyme that indicates such an evolu-
tionary path is the self-splicing group I
intron, which is able to catalyze several
closely related reactions (Forconi and
Herschlag, 2005). A ribozyme was now
found that catalyzes two very different
reaction chemistries, both of which are
coupling ribose and guanine covalently
(Lau and Unrau, 2009). One reaction
creates the N-glycosidic bond as seen in
today’s nucleotides, the other creates
a stable connection via Schiff base
chemistry and Amadori rearrangement.
Therefore, this ribozyme could act as an
evolutionary intermediate between two
ribozymes, each specific for one reaction.
Because this ribozyme probably has the
same global fold for both catalytic activi-
ties, it is the best available evidence for
ribozyme evolution via the third pathway.
Future research may elucidate the evolu-
tionary neighbors of this intersection
sequence, and in vitro selection experi-
ments could show that this evolutionary
pathway actually takes place.
In contrast to RNAs, protein enzymes
appear unable or unlikely to walk the
first or the second evolutionary pathway
because only very few amino acid
sequences specify a stable fold. There-
fore, the first peptides probably evolved
using the third pathway by building
onto an RNA scaffold before being able
to fold independently (Soding and Lu-
pas, 2003). Later evolutionary steps
would have used these independently
folding protein scaffolds to develop new
catalytic activities (Seelig and Szostak,
2007).
Which of the pathways would have
been dominant in an RNA world?
Currently, the numbers of identified ribo-
zymes are on the side of ‘‘escaping the
parent fold’’ (Curtis and Bartel, 2005).
However, the discovery of the promis-
cuous nucleotide synthase ribozyme
(Lau and Unrau, 2009) shows that this
picture is still emerging. Further in vitro
evolution experiments are needed to
determine when a ribozyme follows
a specific evolutionary pathway. For
example, the evolutionary decision could
hinge on the reaction mechanisms or the
evolutionary plasticity of an RNA struc-
ture. However, only after self-replicating
and evolving ribozyme systems are found
(Lincoln and Joyce, 2009) that are
capable of generating ribozymes with
new activities will we be able to pose
these burning questions face-to-face
with our strange RNA ancestors.
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In this issue, Kamisuki and colleagues characterize fatostatin. This compound inhibits the activity of SREBPs,
the master transcription factors of lipid homeostasis. This useful laboratory tool also improved the lipid
profile of obese mice; does this have clinical implications?
Obesity is a growth industry, with no
prospect of downsizing anytime soon.
Associated with cardiovascular disease,
hypertension, and diabetes, obesity has
become a major health burden in the
developed world and is becoming an in-
creasingly prominent issue in developing
countries aswell. Despite the stigma often
attached to lipids in the public conscious-
ness, they are crucial for growth and
development. For instance, fatty acids
and cholesterol are essential for the
synthesis of cell membranes and various
signaling molecules.
At the molecular level, lipid levels are
tightly regulated by the family of sterol-
regulatory element binding proteins
(SREBPs) (Goldstein et al., 2006). These
transcription factors initially reside in
the endoplasmic reticulum (ER), tethered
to SREBP cleavage activating protein
(SCAP). SCAPescorts SREBP to theGolgi
apparatus, where SREBP is processed by
site-1-protease (S1P) and site-2-protease
(S2P) (Figure 1A). This releases themature
form of SREBP, which migrates into the
nucleus to target the genes involved in
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lipid homeostasis. There are
three SREBP isoforms:
SREBP-1c activates genes
involved in fatty acid
synthesis, SREBP-2 upregu-
lates genes involved in
cholesterol synthesis and
uptake, and SREBP-1a
targets both sets of genes
(Goldstein et al., 2006).
These master transcription
factors are elegantly con-
trolled by negative feed-
back; cholesterol and related
sterols retain the SREBP-
SCAP complex in the ER via
the retention protein Insig.
The interaction between
SCAP and Insig is promoted
by cholesterol binding to
SCAPandoxygenated sterols
binding to Insig (Radhak-
rishnan et al., 2007). This
feedback mechanism is ex-
ploited by statins, a class of
commonly used cholesterol-
lowering drugs. Statins
inhibit a rate-limiting step in
cholesterol synthesis (cata-
lyzed by HMG-CoA reduc-
tase), reducing cholesterol
levels and subsequently dere-
pressing SREBP processing.
This upregulates SREBP
target genes, in particular
the gene encoding the low-
density lipoprotein (LDL)
receptor, which imports LDL
(‘‘bad’’ cholesterol) from the
bloodstream, thus reducing
blood-cholesterol levels. However, not all
patients tolerate statins. Hence, there is
a need to examine novel compounds
that manipulate lipid homeostasis to, at
the very least, complement statins.
In this issue of Chemistry and Biology,
Kamisuki and colleagues (2009) explore
the activity of compound 125B11, which
they have bestowed the more catchy
name ‘‘fatostatin.’’ From a library of
10,000 compounds, fatostatin was one
of several compounds that blocked
insulin-induced adipogenesis in cell
culture (Choi et al., 2003). Here, fatostatin
was initially found to reduce the expres-
sion of SREBP target genes, directing
attention to the SREBP transcription
factors. They demonstrated that fatostatin
reduced ER-to-Golgi transport of SREBP
and thus SREBP processing, but how did
this occur?
Using modified fatostatin derivatives,
microscopy revealed that fatostatin inter-
acted with an ER protein, with a binding
assay narrowing down the list of suspects
to SCAP. However, fatostatin did not
affect SCAP’s interaction with SREBP-2
or Insig, and in fact bound to SCAP at
a different site to cholesterol. Thus, the
authors suggest that fatostatin may inter-
fere with the ability of SCAP to interact
with the COPII machinery that is required
for ER-to-Golgi transport. Interestingly,
fatostatin seems to bind to somewhere
within amino acids 449-731 of SCAP—
this contains most of the cytosolic loop
with the MELADL sequence, which is
recognized by the COPII machinery
(Sun et al., 2007). Perhaps
fatostatin interferes with ER-
to-Golgi transport of SREBP
by steric hindrance, prevent-
ing the interaction between
the COPII machinery and
the MELADL sequence within
SCAP? Once the precise
mechanism has been deter-
mined, fatostatin may be
a useful tool to investigate
the SREBP/SCAP pathway,
since it inhibits SREBP trans-
port independently of Insig
and sterols.
Furthermore, could such a
SCAPantagonist be of clinical
importance? Kamisuki and
coworkers (2009) explored
this idea by using ob/ob
mice, a model for obesity.
These mice do not express
functional leptin, which in-
duces satiety, and are thus
unable to control their food
intake. However, these mice
are probably not the best
model for human obesity
because leptin deficiency is
rare in obese humans. Never-
theless, treatment with fato-
statin was found to reduce
weight and improve the lipid
profile of these mice, without
inducing toxicity or affecting
food intake. Genes involved
in fatty acid synthesis were
downregulated in the liver,
reversing fat accumulation
(hepatic steatosis, ‘‘fatty
liver’’). This led to an increase in fatty acids
(free and triglycerides) and ketone bodies
in the bloodstream, suggesting that by in-
hibiting hepatic SREBP-1c activation and
consequently fatty acid synthesis, fatos-
tatin tricks the body into releasing fatty
acid stores from the adipose tissue. This
raises thequestionofwhether or not fatos-
tatin could be a new fat-reducing drug.
Taking a step back, should we consider
SCAP as a candidate for treating obesity?
In fact, siRNA was recently developed
against SCAP in hamster liver (John
et al., 2007), and a patent is in application
for using SCAP-targeted RNAi to treat
conditions that include hyperlipidemia,
obesity, and fatty liver (Soutschek et al.,
2009). Importantly, a SCAP antagonist
would also reduce SREBP-2 processing,
Figure 1. Regulation of Lipid Levels at the Transcriptional Level
(A) The SREBP/SCAP pathway, governed by negative feedback. Details are
provided in the text. Statins inhibit cholesterol synthesis, derepressing the
SREBP/SCAP pathway.
(B) SCAP acts as the middle man, interacting with SREBPs and the COPII
machinery, being negatively regulated by sterols and Insig, and being tran-
scriptionally upregulated by androgens. It is a therapeutic candidate, with
siRNA (Soutschek et al., 2009) and fatostatin (Kamisuki et al., 2009) targeting
SCAP. Steroid analogs such as GW707 have also been proposed to be SCAP
ligands (Grand-Perret et al., 2001), but conflicting evidence has arisen in the
literature (Zhang et al., 2004). Green and red boxes indicate agonists and
antagonists of SCAP, respectively.
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thus preventing cholesterol synthesis.
However, expression of the LDL receptor
would also be affected, thus affecting
cholesterol uptake from the bloodstream.
A high dose of SCAP antagonist would
deplete cellular cholesterol levels. So
would knocking out SCAP in the ob/
ob mice model be lethal? While fatostatin
reduced LDL and high-density lipoprotein
(HDL, ‘‘good cholesterol’’) here, the
authors caution that mice are not a good
model for studying cholesterol homeo-
stasis.
On the other hand, another group
considered the use of steroid analogs
(e.g. GW707), proposing that these
compounds promote SREBP processing
by interactingwith the cholesterol-binding
domain of SCAP (Grand-Perret et al.,
2001). However, these ‘‘SCAP ligands’’
have been more recently shown to block
sterol feedback independently of SCAP
by preventing imported (LDL-) cholesterol
from reaching the ER (Zhang et al., 2004).
Nevertheless, converse to SCAP antago-
nists, a SCAP agonist would increase
LDL-receptor expression and reduce
blood-cholesterol levels, but increase
fatty acid synthesis, resulting in hepatic
steatosis.
Thus, SCAP may be an unsuitable
target for adjusting one’s lipid profile.
Furthermore, taking SCAP out of the
picture would negate the effects of sta-
tins. Approaches to complement statins
could, for instance, involve targeting pro-
protein convertase subtilisin/kexin type 9
(PCSK9), a SREBP-2 target that degrades
the LDL receptor (Chan et al., 2009).
This does not deny the importance of
SCAP in lipid homeostasis, however. In
a prostate cancer (PCa) setting, andro-
gens (male sex hormones) upregulate
SCAP expression, leading to increased
SREBP activity and the intracellular accu-
mulation of neutral lipids (reviewed by
Heemers et al. (2006)). A high-fat Western
diet is associated with PCa risk and
dietary cholesterol augmented PCa
xenograft growth in vivo (Zhuang et al.,
2005), indicating that lipids promote
prostate carcinogenesis. Here, Kamisuki
and colleagues (2009) found that fatosta-
tin blocks the serum-independent growth
of PCa cells, and that knockdown of
SREBP-1c inhibits growth of these cells
in ‘‘fat-free’’ media. From this, they sug-
gested that fatostatin blocks PCa growth
by abolishing SREBP processing. While
this requires further experiments, these
observations suggest that, perhaps, we
should start to explore targeting lipid
metabolism in PCa therapy.
Overall, Kamisuki and coworkers (2009)
have described a compound that may
serve as a valuable tool for studying
SCAP’s role in lipid homeostasis. As
a middle man, SCAP interacts with
SREBPs, Insig, COPII machinery, and
cholesterol, and is upregulated by andro-
gens, so shouldwe consider it to be a ther-
apeutic target (Figure 1B)? Given the diver-
gent regulation of fatty acid and sterol
levels downstream of SCAP, altering
SCAP alone may yield undesirable broad
spectrum effects in treating metabolic
disease but could have potential in the
treatment of tumors.
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